Corporate Member Update: Gilead- U.S. FDA GRANTS ACCELERATED APPROVAL TO TRODELVY® FOR THE TREATMENT OF METASTATIC UROTHELIAL CANCER

U.S. FDA GRANTS ACCELERATED APPROVAL TO TRODELVY® FOR THE TREATMENT OF METASTATIC UROTHELIAL CANCER
– Accelerated Approval Granted for Locally Advanced or Metastatic Urothelial Cancer Following a Platinum-Containing Chemotherapy and a PD-1/PD-L1 Inhibitor – New Indication Marks Second FDA Approval for Trodelvy in 2021 –

Gilead Sciences, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Trodelvy® (sacituzumab govitecan-hziy) for use in adult patients with locally advanced or metastatic urothelial cancer (UC) who have previously received a platinum-containing chemotherapy and either a programmed death receptor-1 (PD-1) or a programmed death-ligand 1 (PD-L1) inhibitor.

Click this link to continue reaading this press release.